Immunotherapy
From the Journals
Inflammatory arthritis induced by ICIs can persist after therapy
The study is “the first to evaluate persistence of ICI-induced IA and identify influential factors on outcome.”
Conference Coverage
Immunotherapies under investigation in newly diagnosed B-ALL
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
Conference Coverage
Adding radiation to immunotherapy may extend PFS in progressive lung cancer
After a median follow-up of 15.2 months, the disease control rate was 57% with the addition of SBRT for patients with metastatic NSCLC who...
From the Journals
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
From the Journals
Nivolumab falls short in ccRCC patients with brain metastases
Nivolumab produced an intracranial response rate of 12% in patients with clear cell renal cell carcinoma and previously untreated brain metastases...
From the Journals
Pretreatment CT data may help predict immunotherapy benefit in ovarian cancer
Fewer sites of disease and lower intratumor heterogeneity on contrast-enhanced CT may indicate a higher likelihood of durable response to immune...
From the Journals
Lichenoid dermatitis with mycosis fungoides features linked to checkpoint inhibitor therapy
A patient treated with immune checkpoint inhibitor therapy for thyroid carcinoma presented with lichenoid dermatitis with mycosis fungoides–like...
Conference Coverage
Bullous disorders linked to frequent interruption of immune checkpoint inhibitor treatment
MILAN – It’s not clear why patients receiving cancer immunotherapy treatment develop bullous pemphigoid.
Conference Coverage
Novel immune checkpoint holds ‘great promise’ as melanoma treatment target
MILAN – A monoclonal antibody directed against DC-HIL reduced melanoma growth and metastasis in animal models.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
Checkpoint inhibitor–induced rheumatic complications have unique features
MADRID – The phenotypic musculoskeletal complications of checkpoint inhibitors do not resemble other joint pathology.